SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates
the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in
SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial
is currently planned at a single center in Navarra.
Phase:
Phase 2
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra